Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT), a clinical-stage biotech developing Bisphosphocin® antimicrobials, appointed David G. Armstrong, DPM, M.D., Ph.D. as Study Chair for its Phase 2a trial of Nu-3 in infected diabetic foot ulcers.

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT), a clinical-stage biotech developing Bisphosphocin® antimicrobials, appointed David G. Armstrong, DPM, M.D., Ph.D. as Study Chair for its Phase 2a trial of Nu-3 in infected diabetic foot ulcers.

Armstrong will also serve as Scientific Advisor for the iDFU program. The proof-of-concept Phase 2a trial will test topical Nu-3 gel at 2%, 5% and 10% to assess safety and efficacy and support a potential Phase 2b study.

Argus Jun 25 session

-7.80% close to close Open Argus

Details

News Market Reaction – LABT

In the Jun 25 session, LABT declined 7.80%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.8% in the session following this news. A negative reaction despite positive clini...

Analysis

The stock moved -7.8% in the session following this news. A negative reaction despite positive clinical progression fits LABT’s history of selling on good news. Recent reverse split and balance sheet concerns could overshadow expert recruitment, keeping focus on funding and trial-execution risks.

Key Figures

Trial phase: Phase 2a Nu-3 dose level: 2% Nu-3 dose level: 5% +1 more

Trial phase

Phase 2a

Proof-of-concept Nu-3 trial in infected diabetic foot ulcers

Nu-3 dose level

2%

One of three topical gel concentrations tested in Phase 2a

Nu-3 dose level

5%

One of three topical gel concentrations tested in Phase 2a

Nu-3 dose level

10%

One of three topical gel concentrations tested in Phase 2a

Historical Context

5 past events · Latest: Jun 22

5 events

1. Jun 22

   IP / patent update

   24h Move

   -7.2%

   New Australian composition of matter patent for Bisphosphocin compounds in infections.

2. Jun 16

   Investor presentation

   24h Move

   -0.7%

   Announcement of presentation at Life Sciences Virtual Investor Forum on June 25, 2026.

3. May 27

   IP / patent expansion

   24h Move

   +3.0%

   New Australia and New Zealand patents expanding Nu-3 gel patent portfolio globally.

4. May 18

   Clinical data update

   24h Move

   -36.6%

   Positive data and CMC progress supporting advancement of Nu-3 for iDFU into Phase 2.

5. May 12

   Trial operations

   24h Move

   +1.9%

   Agreement with PERI to serve as CRO for Nu-3 Phase 2 program, including Phase 2a/2b.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2a, topical antimicrobial, antibiotic resistance

3 terms

phase 2a clinical

"has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

topical antimicrobial medical

"A topical antimicrobial such as Nu-3 fits well with the ongoing evolution of diabetic foot ulcer management"

A topical antimicrobial is a medication or product applied directly to the skin or body surfaces to kill or stop the growth of bacteria, fungi, or other microbes—think of it as a targeted disinfectant for wounds, rashes, or infections. Investors watch these products because approvals, safety, resistance concerns, and whether a product is prescription or over-the-counter affect sales, regulatory risk, and market size much like how a new, safer car model can change demand in an auto market.

antibiotic resistance medical

"antibiotic resistance is a potentially grave concern in this patient population"

Antibiotic resistance is when bacteria change so that antibiotics no longer kill them or stop their growth, making common infections harder to treat. For investors, it is like tools in a toolbox losing effectiveness: it can raise healthcare costs, shorten the useful life of existing drugs, spur demand and regulatory scrutiny for new treatments and diagnostics, and therefore affect revenue, R&D spending and valuations across pharma, biotech and healthcare sectors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program

SARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced that David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, has accepted the position of Study Chair for the Company's Phase 2a clinical trial evaluating Nu-3 for the treatment of infected diabetic foot ulcers (iDFUs). Dr. Armstrong will also serve as a Scientific Advisor to Lakewood-Amedex Biotherapeutics on the iDFU program.

Dr. Armstrong is internationally recognized as one of the world's foremost experts in diabetic foot care, including infection control, wound healing and limb preservation. Throughout his distinguished career, he has authored hundreds of peer-reviewed scientific publications and has helped shape modern approaches to preventing amputations and improving outcomes for patients with diabetes-related complications.

"We are honored to welcome Dr. Armstrong as Study Chair for our Phase 2a trial and as a Scientific Advisor to Lakewood-Amedex Biotherapeutics," said Thomas Balzer, M.D., Ph.D., Chief Medical Officer of Lakewood-Amedex Biotherapeutics. "Dr. Armstrong's unparalleled experience as both a surgeon and investigator in national and international clinical trials brings an important perspective to the study and our advancement of Bisphosphocin^® antimicrobials. We look forward to working closely with him to evaluate the potential of Nu-3 and to further our understanding of how our novel topical antimicrobial therapies may help address persistent challenges in diabetic foot infection management."

As Study Chair, Dr. Armstrong will provide scientific leadership and oversight for the Phase 2a study, helping guide the clinical evaluation of Nu-3, Lakewood-Amedex Biotherapeutics' lead Bisphosphocin^® antimicrobial candidate. The Phase 2a clinical trial is a proof-of-concept study designed to evaluate the safety and efficacy of topical Nu-3 gel in patients with infected diabetic foot ulcers. The study will evaluate three dose concentrations of Nu-3 (2%, 5% and 10%) and is intended to support advancement into a larger Phase 2b clinical study.

"Infected diabetic foot ulcers are a significant clinical challenge despite advances in wound care and limb preservation, and antibiotic resistance is a potentially grave concern in this patient population," said Dr. Armstrong. "There remains a substantial need for new therapeutic approaches that can effectively address infection while supporting healing and minimizing the risk of developing resistance. A topical antimicrobial such as Nu-3 fits well with the ongoing evolution of diabetic foot ulcer management, and if clinical studies demonstrate its effectiveness, it has the potential to help address an important treatment gap for patients suffering from these serious infections. I look forward to working with Lakewood-Amedex Biotherapeutics to evaluate the potential of this novel therapeutic approach."

About David G. Armstrong, DPM, M.D., Ph.D.
David G. Armstrong, DPM, M.D., Ph.D., is Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC and a globally recognized leader in diabetic foot care, wound healing and limb preservation. His research and clinical work have focused on preventing amputations and improving outcomes for patients with diabetes-related complications. Dr. Armstrong has authored hundreds of peer-reviewed scientific publications and is widely regarded as one of the most influential voices in the field of diabetic foot disease and limb preservation.

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin^® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-world-renowned-expert-david-g-armstrong-md-phd-as-study-chair-for-phase-2a-trial-of-nu-3-in-infected-diabetic-foot-ulcers-302809879.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is David G. Armstrong and what is his role in the Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) Nu-3 Phase 2a trial?

David G. Armstrong is a Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC. According to Lakewood-Amedex Biotherapeutics, he will serve as Study Chair for the Nu-3 Phase 2a trial and as Scientific Advisor for the iDFU program.

What is Nu-3 and what does the Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) Phase 2a trial evaluate?

Nu-3 is Lakewood-Amedex Biotherapeutics’ lead Bisphosphocin antimicrobial candidate formulated as a topical gel. According to Lakewood-Amedex Biotherapeutics, the Phase 2a proof-of-concept study evaluates the safety and efficacy of topical Nu-3 in patients with infected diabetic foot ulcers.

What dose levels of Nu-3 are tested in the Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) Phase 2a study for infected diabetic foot ulcers?

The Nu-3 Phase 2a trial evaluates three topical gel dose concentrations in infected diabetic foot ulcer patients. According to Lakewood-Amedex Biotherapeutics, the study is testing Nu-3 at 2%, 5% and 10% concentrations to assess safety and efficacy across multiple dosing levels.

What is the main purpose of the Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) Nu-3 Phase 2a trial in infected diabetic foot ulcers?

The Nu-3 Phase 2a trial is designed as a proof-of-concept clinical study. According to Lakewood-Amedex Biotherapeutics, it aims to evaluate safety and efficacy of topical Nu-3 gel and generate data intended to support advancement into a larger Phase 2b clinical trial.

How could Nu-3 potentially help patients with infected diabetic foot ulcers in the Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) program?

Nu-3 is being studied as a topical antimicrobial for infected diabetic foot ulcers. According to Lakewood-Amedex Biotherapeutics and Dr. Armstrong, if clinical studies demonstrate effectiveness, Nu-3 may help address infection while supporting healing and could fill an important treatment gap in diabetic foot infection management.